Artificial Cells Nanomedicine and Biotechnology

Artificial Cells Nanomedicine and Biotechnology is an open access journal published by Taylor & Francis, founded in 1973 and devoted to artificial cells, nanomedicine and health-related biotechnology, with a 2025 Journal Impact Factor of 5.6.《人工细胞、纳米医学与生物技术》（Artificial Cells Nanomedicine and Biotechnology）由（Taylor & Francis）出版，1973 年创刊，专注人工细胞、纳米医学与健康相关生物技术，2025 年期刊影响因子为 5.6。

Scope

• The journal publishes high-quality open access research at the convergence of artificial cells, nanomedicine and health-related biotechnology, with emphasis on original studies that demonstrate game-changing and disruptive technologies, new concepts and innovative experimental approaches.本刊发表人工细胞、纳米医学与健康相关生物技术交叉领域的开放获取研究，侧重具有突破性与颠覆性技术、新概念和创新实验方法的原创研究。
• Its remit covers synthetic biology, synthetic organelles and build-a-cell approaches, artificial exosomes and extracellular vesicles, synthetic genomics, self-assembly and origins of life.征稿范围涵盖合成生物学、合成细胞器与自建细胞方法、人工外泌体与细胞外囊泡、合成基因组学、自组装及生命起源研究。
• Artificial cells are followed as biotherapeutics and immunotherapeutics, including stem cell therapy, blood substitutes and oxygen therapeutics, novel carriers for vaccines and drugs, and bio-immunosorbent therapy.人工细胞方向覆盖生物治疗与免疫治疗（含干细胞治疗）、血液替代品与氧疗、疫苗与药物的新型载体以及生物免疫吸附疗法。
• The nanomedicine side spans bio and molecular nanosystems, nanoparticles and nanoscale therapeutics, smart and stimuli-responsive nanobiosystems, human physiology mimicking models such as organ-on-chip, and nanotoxicology.纳米医学一侧涵盖生物与分子纳米系统、纳米颗粒与纳米级治疗剂、智能刺激响应纳米生物系统、器官芯片等仿人体生理模型以及纳米毒理学。
• Also inside scope are mechanobiology, mechanopharmacology and mechanomedicine, precision nanomedicine, biomedical sensors and sensor fusion, nanofabrication and nanopatterning, single particle and single cell analysis, and biomedical imaging.机械生物学、机械药理学与机械医学、精准纳米医学、生物医学传感器与传感融合、纳米制造与纳米图案化、单颗粒与单细胞分析以及生物医学成像，亦在收录之列。
• A third pillar is the convergence of information science, nanoscale science and molecular biology, the nano-bio-info-cogno field, including integrated platforms for bioinformatics, cognition and prediction.第三大支柱是信息科学、纳米科学与分子生物学的交汇，即（nano-bio-info-cogno）领域，包括生物信息学、认知与预测的一体化平台。
• The journal accepts original papers, reviews, method articles, data notes and registered reports, while editorials appear by invitation only.本刊接受原创论文、综述、方法文章、数据简报与注册报告，编辑部文章仅限邀稿。

History

• The title began in 1973 as Biomaterials, Medical Devices, and Artificial Organs and passed through three further names before taking its present form.本刊 1973 年创刊时名为（Biomaterials, Medical Devices, and Artificial Organs），三度更名后定为现名。
• It became Biomaterials, Artificial Cells and Artificial Organs in 1987 and Biomaterials, Artificial Cells and Immobilization Biotechnology in 1991.1987 年更名为（Biomaterials, Artificial Cells and Artificial Organs），1991 年再度更名为（Biomaterials, Artificial Cells and Immobilization Biotechnology）。
• From 1994 to 2012 it appeared as Artificial Cells, Blood Substitutes, and Biotechnology, reflecting a long tradition in blood substitute research.1994 年至 2012 年间刊名为（Artificial Cells, Blood Substitutes, and Biotechnology），体现其在血液替代品研究上的悠久传统。
• The journal was renamed Artificial Cells, Nanomedicine, and Biotechnology in 2013 to match its interdisciplinary scope.2013 年更名为现名（Artificial Cells, Nanomedicine, and Biotechnology），以契合其交叉学科定位。
• It is now a fully open access title that publishes online only, and articles appear under a continuous publication model.本刊现为完全开放获取刊物，仅在线出版，论文按连续出版模式发表。
• The 2025 Journal Impact Factor is 5.6, ranking the journal 38/180 in Biotechnology and Applied Microbiology in Q1, and the 2025 CiteScore is 8.5.2025 年期刊影响因子为 5.6，在生物工程与应用微生物学类别中位列 38/180（Q1），Scopus 2025 年（CiteScore）为 8.5。
• An article processing charge applies, which DOAJ lists as up to USD 2,990 per paper, with waivers and institutional discounts available and the publisher fee finder carrying the authoritative figure.本刊收取文章处理费，（DOAJ）载明其上限为每篇 2,990 美元，并设有减免与机构协议优惠，具体金额以出版方费用查询工具为准。^[1]

Editors

• Taylor & Francis lists two co-editors-in-chief, RDK Misra of Lawrence Technological University in Michigan and Wojciech Chrzanowski of the University of Sydney.（Taylor & Francis）列出的共同主编为（Lawrence Technological University）的（RDK Misra）与（University of Sydney）的（Wojciech Chrzanowski）。
• Paul Roach of Loughborough University serves as reviews editor.（Loughborough University）的（Paul Roach）任评论编辑。
• Thomas M. S. Chang, emeritus professor at McGill University and director of its Artificial Cells and Organs Research Centre, is emeritus editor.（McGill University）荣休教授、该校（Artificial Cells and Organs Research Centre）主任（Thomas M. S. Chang）为荣誉编辑。
• Seven associate editors come from universities in India, Israel, Egypt, South Africa, the United States, Canada and Australia.七位副主编分别来自印度、以色列、埃及、南非、美国、加拿大与澳大利亚的高校。
• The editorial board counts 24 members from some 20 countries, spanning North America, Europe, the Middle East, Africa and Asia.编委会由 24 位成员组成，来自约 20 个国家，覆盖北美、欧洲、中东、非洲与亚洲。
• Review is single anonymized, the average time from submission to first decision is nine days and the reported acceptance rate is 21%.评审采用单匿名方式，自投稿至首次决定平均 9 天，官方公布的录用率为 21%。